Table 5.
Predictors of outcomes.
| 2 yr LC | p-value | ||
|---|---|---|---|
| Sex | |||
| Male (n = 22) | 90 % | 0.136 | |
| Female (n = 27) | 62 % | ||
| Age at RT, yrs | |||
| <60 (n = 22) | 74 % | 0.818 | |
| ≥60 (n = 27) | 82 % | ||
| Primary mucosal melanoma | |||
| No (n = 38) | 82 % | 0.04 | |
| Yes (n = 11) | 60 % | ||
| BRAF mutation | |||
| Absent (n = 26) | 80 % | 0.394 | |
| Present (n = 18) | 75 % | ||
| Prior 2+ lines systemic therapy | |||
| No (n = 20) | 81 % | 0.618 | |
| Yes (n = 29) | 70 % | ||
| Prior local therapy to target site | |||
| No (n = 39) | 85 % | 0.289 | |
| Yes (n = 14) | 62 % | ||
| RT target was unresectable or oligometastatic | |||
| No (n = 30) | 69 % | 0.563 | |
| Yes (n = 23) | 85 % | ||
| Target size | |||
| ≤5 cm (n = 24) | 69 % | 0.478 | |
| >5 cm (n = 29) | 88 % | ||
| EQD2α/β=3 54 Gy+ | |||
| No (n = 19) | 67 % | 0.26 | |
| Yes (n = 34) | 88 % | ||
| Tumor shrinkage after RT | |||
| No (n = 14) | 60 % | 0.004 | |
| Yes (n = 39) | 93 % | ||
EQD2α/β=354 Gy+: Prescription dose to GTV was equal to or greater than 54 Gy, n = number of patients, RT: radiation therapy.